The overarching aim of the Virology Core is to provide key infrastructure support to the basic, translational, and clinical research capacity of the Emory/Atlanta community in the fields of HIV infection and AIDS. This goal is achieved by providing state-of-the-art technology and resources for all relevant clinical and preventive studies of human subjects (Clinical component) and SIV/SHIV-infected non-human primates (Pre-Clinical component). In addition, the Core provides key leadership in this research area through collaboration, training, and mentoring. The overall goal of the Core will be accomplished through the following Specific Aims: 1. To expand the range of existing assays for quantification of all aspects of SIV/SHIV infection and replication that are essential to the study of AIDS pathogenesis, therapy, and prevention in non-human primates. 2. To expand the menu of tests needed to support clinical studies/trials of HIV-1 infections and co-infections, provide testing in a CLIA certified laboratory, and provide economy of scale through provision of shared resources. 3. To provide technical and intellectual support, including consultation and training opportunities, to local, national, and international AIDS research efforts that include both non-human primates and human infections. 4. To facilitate academic and industrial development of novel AIDS therapy and prevention programs through provision of virological services. The Emory CFAR Virology Core will continue to provide crucial support for the HIV/AIDS research programs by establishment of a world-class, highly recognized service laboratory that offers a broad repertoire of cutting edge virological and gene expression assays.
Through the provision of viral quantification and gene expression services, the Virology Core will play a crucial role in the fight to prevent infection, treat those living with AIDS and ultimately eradicate HIV/AIDS. The numerous research projects that the Core supports will be instrumental in developing a preventive vaccine, discovering new novel therapeutics, and understanding the mechanisms of AIDS pathogenesis.
|Kannanganat, Sunil; Wyatt, Linda S; Gangadhara, Sailaja et al. (2016) High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5Î±-Restrictive Macaques. J Immunol 197:3586-3596|
|Kelley, Colleen F; Lai, Lilin; Ibegbu, Chris et al. (2016) Differences in expression of gut-homing receptors on CD4+ T cells in black and white HIV-negative men who have sex with men. AIDS 30:1305-8|
|Anderson, Albert M; Lennox, Jeffrey L; Nguyen, Minh L et al. (2016) Preliminary study of a novel cognitive assessment device for the evaluation of HIV-associated neurocognitive impairment. J Neurovirol 22:816-822|
|Kalokhe, Ameeta S; Ibegbu, Chris C; Kaur, Surinder P et al. (2016) INTIMATE PARTNER VIOLENCE IS ASSOCIATED WITH INCREASED CD4(+) T-CELL ACTIVATION AMONG HIV-NEGATIVE HIGH-RISK WOMEN. Pathog Immun 1:193-213|
|HernÃ¡ndez-Romieu, Alfonso C; del Rio, Carlos; HernÃ¡ndez-Ãvila, Juan Eugenio et al. (2016) CD4 Counts at Entry to HIV Care in Mexico for Patients under the "Universal Antiretroviral Treatment Program for the Uninsured Population," 2007-2014. PLoS One 11:e0152444|
|White, Darcy; Grey, Jeremy A; Gorbach, Pamina M et al. (2016) Racial Differences in Partnership Attributes, Typologies, and Risk Behaviors Among Men Who Have Sex With Men in Atlanta, Georgia. Arch Sex Behav :|
|Sun, Xiaoyan; Peng, Limin; Huang, Yijian et al. (2016) Generalizing Quantile Regression for Counting Processes with Applications to Recurrent Events. J Am Stat Assoc 111:145-156|
|Ravindran, Rajesh; Loebbermann, Jens; Nakaya, Helder I et al. (2016) The amino acid sensor GCN2 controls gut inflammation by inhibiting inflammasome activation. Nature 531:523-7|
|Nasri, Hashem; Kabbani, Sarah; Bou Alwan, Melhim et al. (2016) Retrospective Study of Cryptococcal Meningitis With Elevated Minimum Inhibitory Concentration to Fluconazole in Immunocompromised Patients. Open Forum Infect Dis 3:ofw076|
|Haile, Woldeab B; Gavegnano, Christina; Tao, Sijia et al. (2016) The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model. Neurobiol Dis 92:137-43|
Showing the most recent 10 out of 817 publications